

22 - References

References

948 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 14 References

1. EMC. Summary of Product Characteristics. 2024; <http://www.medicines.org.uk/emc/>.
2. Baldwin D, et al. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. *BMJ* 2011; 342:d1199.
3. Bolam v Friern Barnet Hospital Management Committee [1957] 1 WLR582.
4. Bolitho v City and Hackney Health Authority [1997] 3 WLR1151.
5. British and Irish Legal Information Institute. Montgomery (Appellant) v Lanarkshire Health Board (Respondent) (Scotland). 2015; <http://www.bailii.org/uk/cases/UKSC/2015/11.html>.
6. General Medical Council. Good practice in prescribing and managing medicines and devices. 2021 (last checked September 2024); https://www.gmc-uk.org/guidance/ethical_guidance/14316.asp.
7. Buckman Co. v. Plaintiffs' Legal Comm. 531 U.S. 341. 2001; <https://www.law.cornell.edu/supct/html/98-1768.ZO.html>.
8. FindLaw. Off-label use promotion is protected free speech. 2019 (last accessed September 2024); <https://www.findlaw.com/legalblogs/second-circuit/off-label-use-promotion-is-protected-free-speech/>.
9. Vijay A, et al. Patterns and predictors of off-label prescription of psychiatric drugs. *PLoS One* 2018; 13:e0198363.
10. Leslie DL, et al. Off-label use of antipsychotic medications in Medicaid. *Am J Manag Care* 2012; 18:e109-117.
11. Ishtiak-Ahmed K, et al. Treatment indications and potential off-label use of antidepressants among older adults: a population-based descriptive study in Denmark. *Int J Geriatr Psychiatry* 2022; 37:10.1002/gps.5841.
12. Martínez CE, et al. Antidepressant use and off-label prescribing in primary care in Spain (2013-2018). *An Pediatr (Engl Ed)* 2022; 97:237-246.
13. Hefner G, et al. Off-label use of antidepressants, antipsychotics, and mood-stabilizers in psychiatry. *J Neural Transm (Vienna)* 2022; 129:1353-1365.
14. Epstein RS, et al. The many sides of off-label prescribing. *Clin Pharmacol Ther* 2012; 91:755-758.
15. Wong J, et al. Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system. *BMJ* 2017; 356:j603.
16. Royal College of Psychiatrists. Use of licensed medicines for unlicensed applications in psychiatric practice (2nd edition) (CR210 Dec 2017). 2017 (last accessed September 2024); <https://www.rcpsych.ac.uk/improving-care/campaigning-for-better-mental-health-->

policy/college-reports/2017-college-reports/use-of-licensed-medicines-for-unlicensed-applications-in-psychiatric-practice-2nd-edition-cr210-dec-2017.

17. American Psychiatric Association. APA official actions: position statement on off-label treatments. 2021 (last accessed September 2024);
<https://www.psychiatry.org/getattachment/053eae03-9e23-422f-ab75--2ea052eb6c81/Position-Off-Label-Treatments.pdf>.
 18. Royal Australian New Zealand College of Psychiatrists (RANZCP). 'Off-label' prescribing in psychiatry. Professional Practice Guideline 4. 2023 (last accessed September 2024);
<https://www.ranzcp.org/getmedia/edc66b1d-005b-411d-b277-5c7fddc71ba2/ppg-4-off-label-prescribing-december-2023.pdf>.
-

Revision #1

Created 2026-01-04 20:18:37 UTC by Omar Ayman

Updated 2026-01-04 20:18:37 UTC by Omar Ayman